CBDV is a cannabinoid that acts much like CBD. It can help with mood disorders, healthy cellular function, and controlling nausea.
It is currently being studied for childhood intractable epilepsy and Rett Syndrome, a genetic disorder that causes seizures and speech problems in girls. It also has the potential to ease the symptoms of DMD, a progressive form of muscular dystrophy.
CBDV is a Cannabinoid
What is CBDV? CBDV (cannabidivarin) is one of 113 known cannabinoids in the cannabis or hemp plant. It has similar properties to cannabidiol, and the two compounds have similar structures, which is why it’s often used in studies on patients with autism spectrum disorder. CBDV has been shown to alleviate behavioral and communication issues, reduce acute anxiety, and inhibit chemically-induced seizures in animal tests. It also has the potential to help treat Rett syndrome, a genetic mutation that primarily impacts women and affects their ability to speak, walk, and use their hands.
CBDV is a non-psychoactive cannabinoid that works through the Endocannabinoid System (ECS). It interacts with receptors in the ECS to prevent nausea and other uncomfortable symptoms. It has also been shown to improve locomotion in a model of Duchenne muscular dystrophy, a condition that causes inflammation and irreversible damage to skeletal muscle tissue. It is currently being researched as an anticonvulsant for treating autism spectrum disorders by pharmaceutical giant GW Pharma.
CBDV is a Compound
CBDV is a phytocannabinoid and part of the cannabis plant’s complex phytochemical profile. It’s usually present in lower concentrations than THC and CBD. Like THC and CBD, it is a cannabinoid that delivers unique and therapeutic effects that are best enjoyed in full-spectrum extracts that mimic the natural phytochemical composition of the plant.
CBDV has shown promise in managing seizures and delivering mood and gastrointestinal benefits. It has been a subject of clinical trials run by pharmaceutical companies such as GW Pharmaceuticals with their Epidiolex drug, which is currently approved for treating rare epilepsy. CBDV has also been studied in rodents and found to have anticonvulsant properties, aiding in a range of neurological conditions, including autism spectrum disorders.
CBDV was discovered over 50 years ago but has been relatively obscure until recently when research on it picked up speed. Studies on mice with Rett Syndrome have shown that CBDV can help reduce seizures, increase motor coordination, and improve sociability deficits.
CBDV is a Synthetic Cannabinoid
CBDV, also known as cannabidivarin, is a cannabinoid with similar structures to the more well-known compounds, including THC and CBD. The difference is that CBDV has two methyl groups removed, making it less psychoactive.
Although CBDV was discovered in the cannabis plant over 50 years ago, it is relatively new to formal medical research. Its potential for reducing seizures and easing anxiety is drawing the attention of investors in pharmaceutical companies.
CBDV is found in strains of marijuana that have lower THCD9-tetrahydrocannabinol and higher CBD-cannabidiol contents. It is usually found in Indica dominant strains, particularly those from Africa, Asia, and South America.
CBDV has shown anticonvulsant properties and effectively lowers the frequency and severity of seizures in animal studies. It works by stimulating our endocannabinoid system, but unlike THC, CBDV doesn’t have a high affinity for CB1 or CB2 receptors. It has been found to activate and desensitize TRPV1 receptors, reducing epileptic activity in the hippocampus.
CBDV is a Natural Cannabinoid
Cannabidivarin, or CBD, is a naturally-occurring cannabinoid found in cannabis. It has been shown to have anticonvulsant effects and other potential therapeutic benefits. This is because CBDv binds to TRPV receptors, which mediate pain perception and body temperature. CBD also binds to TRPA1 receptors, known for their vasodilatory and anti-nausea properties.
Currently, CBDV is being investigated as a treatment for autism spectrum disorder (ASD). It has been found to alleviate symptoms of the condition, such as lowered anandamide levels and decreased social engagement. CBDV is believed to interact with the endocannabinoid system to help reduce tremors, anxiety, and mood swings.
It also inhibits chemically induced seizures and increases neurobehavioral function in mice. Additionally, a study on Rett syndrome, a genetic mutation that impacts women, showed CBDV effectively improves neurobehavioral issues in the affected patients. It was found to do this by interacting with the endocannabinoid systems to regulate cellular function.